Rapid enlargement of cardiac rhabdomyoma during corticotropin therapy for infantile spasms

Can J Cardiol. 1997 Jan;13(1):72-4.

Abstract

Objective: To investigate the influence of corticotropin therapy on cardiac rhabdomyoma.

Design: Analysis of data from echocardiography performed on in-patients.

Patients: Six patients with rhabdomyoma who were admitted to the authors' medical centre with either convulsion (five cases) or prematurity (one case) between 1985 and 1995. Five had tuberous sclerosis.

Intervention: Size of cardiac tumours of each patient was measured by echocardiography, and volume index was calculated as the ratio of the tumour volume to its initial volume.

Main result: Increase in size of some of the tumours was found during corticotropin therapy on follow-up echocardiography. Maximum volume indexes of tumours in the case of patients (n = 4) who did not receive corticotropin therapy was 1.2 to 3.7, whereas those of patients (n = 2) who received therapy was 9.1 to 12; one of the latter patients died.

Conclusion: Corticotropin may contribute to the enlargement of cardiac rhabdomyoma. The size of cardiac rhabdomyomas must be carefully followed when patients are treated with corticotropin.

MeSH terms

  • Adrenocorticotropic Hormone / adverse effects*
  • Adrenocorticotropic Hormone / therapeutic use
  • Echocardiography
  • Heart Neoplasms / diagnostic imaging
  • Heart Neoplasms / etiology
  • Heart Neoplasms / pathology*
  • Humans
  • Infant
  • Infant, Newborn
  • Recurrence
  • Rhabdomyoma / diagnostic imaging
  • Rhabdomyoma / etiology
  • Rhabdomyoma / pathology*
  • Seizures / drug therapy*
  • Seizures / etiology
  • Tuberous Sclerosis / complications

Substances

  • Adrenocorticotropic Hormone